Literature DB >> 625136

Incidence of emboli with cloth-covered Starr-Edwards valve without anticoagulation and with varying forms of anticoagulation. Analysis of 183 patients followed for 3 1/2 years.

R A Moggio, G L Hammond, H C Stansel, W W Glenn.   

Abstract

One hundred eighty-three patients with cloth-covered valves were studied from 1 1/2 to 8 years after operation, with an average follow-up time of 3 1/2 years. Over the total period, patients taking Coumadin sustained a 4 percent embolic incidence (1.2 per 100 patient-years); those taking aspirin had a 7 percent incidence (2.6 per 100 patient-years); and those taking Persantine had a 43 percent incidence (10 per 100 patient-years). Patients on no regimen of anticoagulation had a 16 percent embolic rate (four per 100 patient-years), whereas another group of patients who stopped anticoagulants after a year incurred a 13 percent embolic incidence in the subsequent 2 years (6.4 per 100 patient-years). These data showed a significantly lowered embolic rate with anticoagulation and suggest that all patients with cloth-covered valves should be taking anticoagulants. That these valves become epithelialized and do not form thrombus after a year was not borne out by this study. Persantine alone is not a satisfactory anticoagulant. Coumadin appears to be the superior anticoagulant, but if careful monitoring of its use is in question or if serious bleeding complications ensue, aspirin may provide satisfactory protection.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 625136

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Valve replacement in children under 15 years with rheumatic heart disease.

Authors:  F Abid; N Mzah; F el Euch; M Ben Ismail
Journal:  Pediatr Cardiol       Date:  1989       Impact factor: 1.655

2.  Mitral valve annuloplasty: results in an underdeveloped population.

Authors:  M J Antunes; R H Kinsley
Journal:  Thorax       Date:  1983-10       Impact factor: 9.139

Review 3.  Aspirin in cardiovascular disease.

Authors:  I A Reilly; G A FitzGerald
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

Review 4.  Antiplatelet drugs: clinical pharmacology and therapeutic use.

Authors:  A S Gallus
Journal:  Drugs       Date:  1979-12       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.